In clinical studies, Rasilamlo demonstrated reductions in blood pressure than Rasilez and amlodipine alone.
The study results suggested that the use of single-pill combinations like Rasilamlo can provide a convenient new treatment option for patients with uncontrolled blood pressure.
Novartis Pharma Division head David Epstein said they are pleased to announce that following the EC approval Rasilamlo will now be available to high blood pressure patients in the EU who are not controlled by either aliskiren or amlodipine alone.
University of Glasgow Institute of Cardiovascular & Medical Sciences Gordon McInnes said research has shown that patients receiving two blood pressure medications in a single-pill combination are more likely to adhere to treatment than those receiving two single medications in combination, highlighting the need for innovative new single-pill combinations to treat high blood pressure.